Search

Your search keyword '"Petua P"' showing total 4 results
Start Over Author "Petua P" Publication Year Range Last 3 years
4 results on '"Petua P"'

1. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Author

Bruel, Timothée, Vrignaud, Lou-Léna, Porrot, Françoise, Staropoli, Isabelle, Planas, Delphine, Guivel-Benhassine, Florence, Puech, Julien, Prot, Matthieu, Munier, Sandie, Bolland, William Henry, Soulié, Cathia, Zafilaza, Karen, Lusivika-Nzinga, Clovis, Meledge, Marie-Laure, Dorival, Céline, Molino, Diana, Péré, Hélène, Yordanov, Youri, Simon-Lorière, Etienne, Veyer, David, Carrat, Fabrice, Schwartz, Olivier, Marcelin, Anne-Geneviève, Martin-Blondel, Guillaume, Garcia, Magalie, Giraud, Valentin, Metais, Agathe, Cazenave-Roblot, Fance, Martellosio Anne-Marie Ronchetti, Jean-Philippe, Gabas, Thomas, Hadjadj, Naima, Salanoubat, Célia, Chabrol, Amélie, Housset, Pierre, Pardon, Agathe, Faucon, Anne-Laure, Caudwell, Valérie, Roland Liblau, Latifa Hanafi, Alric, Laurent, Pugnet, Grégory, Mourguet, Morgane, Bories, Eva, Bonnet, Delphine, Charpentier, Sandrine, Delobel, Pierre, Debard, Alexa, Beck, Colleen, Boumaza, Xavier, Fanny Lanternier, Stella Rousset, Delage, Claire, Pires, Elisabete Gomes, Cheminant, Morgane, Anthony Chauvin, Nathalie Chavarot, Véronique Delcey Simon Bessis, Xavier Eyer, Cresta, Mélanie, Pélagie Thibaut, Romain Gueneau, Nadal, Marine, Siguier, Martin, Bachir, Marwa, Valérie Pourcher, Christia Palacios, Melenotte, Cléa, Faycal, Antoine, Berot, Vincent, Brin, Cécile, Djebara, Siham, Zafilaza, Karen, Marot, Stéphane, Sayon, Sophie, Leducq, Vincent, Malet, Isabelle, Teyssou, Elisa, Karine Lacombe, Adélie Gothland, Aad, Yasmine Abi, Chiarabini, Thibault, Feliho, Raynald, Valin, Nadia, Brigant, Fabien, Boize, Julien, Thiébaud, Pierre-Clément, Moreau, Marie, Nathalie De Castro, Charlotte Billard, Liégeon, Geoffroy, Denis, Blandine, Molina, Jean-Michel, André Cabié, Lucia Etheve, Abel, Sylvie, Cabras, Ornella, Guitteaud, Karine, François Vincent Dubee, Sandrine Pierre-, Ndiaye, Diama, Pehlivan, Jonathan, Phelippeau, Michael, Alexandre Duvignaud, Rafael Mahieu, Pistone, Thierry, Desclaux, Arnaud, Neau, Didier, Jean-François Faucher, Charles Cazanave, Festou, Benjamin, Dupuy-Grasset, Magali, Loustaud-Ratti, Véronique, Nathan Peiffer- Smadja, Delphine Chainier, Choquet, Christophe, Da Conceicao, Olivia, Thy, Michael, Collas, Lio, Godard, Cindy, Bouzid, Donia, Ing, Vittiaroat, Pereira, Laurent, Pavlowsky, Thomas, RavautAntoine Asquier-Khati, Camille, Boutoille, David, Chauveau, Marie, Deschanvres, Colin, Audrey Le Bot, François Raffi, Cailleaux, Marine, Benezit, François, Maillard, Anne, Hue, Benoit, François Coustilleres, Pierre Tattevin, Carvalho-Schneider, Claudia, Jamard, Simon, Petit, Laeticia, Natacha Mrozek, Karl Stefic, Theis, Clément, Vidal, Magali, Sauvat, Léo, Benjamin Lefèvre, Delphine Martineau, Baronnet, Guillaume, Florence Ader, Agnès Didier, Perpoint, Thomas, Conrad, Anne, Chabert, Paul, Aurélie Martin, Pierre Chauvelot, Loubet, Paul, Mazet, Julien, Larcher, Romaric, Mathilde Devaux Jérôme Frey, Didier Laureillard, Woerlen, Amos, Remillon, Aline, Absensur-Vuillaume, Laure, Albert Trinh-Duc, Pauline Bouquet, Philippe Petua, Patrick Rispal, Aurore Perrot, Julien Carillo, Delavigne, Karen, Cougoul, Pierre, Dion, Jérémie, Mathieu Blot, Odile Rauzy, Sixt, Thibault, Moretto, Florian, Charles, Carole, Sophie Circosta, Lionel Piroth, Leger, Lydia, Arulananthan, Arulvani, Lascoux, Carine, Valérie, Pascaline, Yazdan Yazdanpanah, Leia Becam, Petrov-Sanchez, Ventzislava, Diallo, Alpha, Le Mestre, Soizic, Le Meut Isabelle Goderel, Guillaume, Chau, Frédéric, Soltana, Brahim, Chane Tang, Jessica, Guedj, Jérémie, and Caille, Yvanie

Abstract

Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.

Published
2023
Full Text
View/download PDF

2. Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)

Author

Reignier, Jean, Plantefeve, Gaetan, Mira, Jean-Paul, Argaud, Laurent, Asfar, Pierre, Aissaoui, Nadia, Badie, Julio, Botoc, Nicolae-Vlad, Brisard, Laurent, Bui, Hoang-Nam, Chatellier, Delphine, Chauvelot, Louis, Combes, Alain, Cracco, Christophe, Darmon, Michael, Das, Vincent, Debarre, Matthieu, Delbove, Agathe, Devaquet, Jérôme, Dumont, Louis-Marie, Gontier, Olivier, Groyer, Samuel, Guérin, Laurent, Guidet, Bertrand, Hourmant, Yannick, Jaber, Samir, Lambiotte, Fabien, Leroy, Christophe, Letocart, Philippe, Madeux, Benjamin, Maizel, Julien, Martinet, Olivier, Martino, Frédéric, Maxime, Virginie, Mercier, Emmanuelle, Nay, Mai-Anh, Nseir, Saad, Oziel, Johanna, Picard, Walter, Piton, Gael, Quenot, Jean-Pierre, Reizine, Florian, Renault, Anne, Richecoeur, Jack, Rigaud, Jean-Philippe, Schneider, Francis, Silva, Daniel, Sirodot, Michel, Souweine, Bertrand, Tamion, Fabienne, Terzi, Nicolas, Thévenin, Didier, Thiery, Guillaume, Thieulot-Rolin, Nathalie, Timsit, Jean-Francois, Tinturier, Francois, Tirot, Patrice, Vanderlinden, Thierry, Vinatier, Isabelle, Vinsonneau, Christophe, Voicu, Sebastian, Lascarrou, Jean-Baptiste, Le Gouge, Amélie, Contou, Damien, Pajot, Olivier, Jaubert, Paul, Marin, Nathalie, Simon, Marie, Cour, Martin, Mortaza, Satar, Souday, Vincent, Lemerle, Marie, Malfroy, Sylvain, Berdaguer Ferrari, Fernando, Rozec, Bertrand, Gruson, Didier, Sazio, Charline, Champion, Suzanne, Boissier, Florence, Veinstein, Anne, Baboi, Loredana, Richard, Jean-Christophe, Yonis, Hodane, Le Guennec, Loïc, Lefevre, Lucie, Chommeloux, Juliette, Hékimian, Guillaume, Lemiale, Virginie, Mariotte, Eric, Valade, Sandrine, Tirolien, Joanna, Fedun, Yannick, Cerf, Charles, Tachon, Guillaume, Roustan, Jérôme, Vimeux, Sylvie, Bonnivard, Michel, Anguel, Nadia, Osman, David, Asehnoune, Karim, Roquilly, Antoine, Belafia, Fouad, Conseil, Matthieu, Cisse, Moussa, Chaouki, Bouras, Espenel, Rémi, Brasse, Christine, Ena, Sébastien, Delahaye, Arnaud, Castanera, Jeremy, Dulac, Thierry, Petua, Philippe, Zerbib, Yoann, Brault, Clément, Annane, Djillali, Bounab, Rania, Heming, Nicholas, Boulain, Thierry, Jacquier, Sophie, Muller, Grégoire, Favory, Raphael, Préau, Sébastien, Poissy, Julien, Massri, Alexandre, Lissonde, Floriane, Winiszewski, Hadrien, Vieille, Thibault, Jacquier, Marine, Labruyère, Marie, Andreu, Pascal, Tadié, Jean-Marc, Bodenes, Laetitia, Combaux, Danièle, Luis, David, Marchalot, Antoine, Herbrecht, Jean-Etienne, Clere-Jehl, Raphaël, Schnell, David, Aboad, Jérôme, Bougon, David, Escudier, Etienne, Coupez, Elisabeth, Dupuis, Claire, Demailly, Zoe, Galerneau, Louis-Marie, Chelly, Jonathan, Pourcine, Franck, Van Vong, Ly, Abid, Sonia, De Montmollin, Etienne, Sonneville, Romain, Guitton, Christophe, Chudeau, Nicolas, Landais, Mickaël, Pages, Vincent, Séjourné, Caroline, Rahmani, Imen, Sbouj, Ghada, Megarbane, Bruno, Deye, Nicolas, and Malissin, Isabelle

Abstract

The optimal calorie and protein intakes at the acute phase of severe critical illness remain unknown. We hypothesised that early calorie and protein restriction improved outcomes in these patients, compared with standard calorie and protein targets.

Published
2023
Full Text
View/download PDF

3. Protocol for fever control using external cooling in mechanically ventilated patients with septic shock: SEPSISCOOL II randomised controlled trial.

Author

Guénégou-Arnoux A, Murris J, Bechet S, Jung C, Auchabie J, Dupeyrat J, Anguel N, Asfar P, Badie J, Carpentier D, Chousterman B, Bourenne J, Delbove A, Devaquet J, Deye N, Dumas G, Dureau AF, Lascarrou JB, Legriel S, Guitton C, Jannière-Nartey C, Quenot JP, Lacherade JC, Maizel J, Mekontso Dessap A, Mourvillier B, Petua P, Plantefeve G, Richard JC, Robert A, Saccheri C, Vong LVP, Katsahian S, and Schortgen F

Subjects
Humans, Respiration, Artificial, Pilot Projects, Fever therapy, Fever complications, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Shock, Septic therapy, Shock, Septic complications, Sepsis complications
Abstract

Introduction: Fever treatment is commonly applied in patients with sepsis but its impact on survival remains undetermined. Patients with respiratory and haemodynamic failure are at the highest risk for not tolerating the metabolic cost of fever. However, fever can help to control infection. Treating fever with paracetamol has been shown to be less effective than cooling. In the SEPSISCOOL pilot study, active fever control by external cooling improved organ failure recovery and early survival. The main objective of this confirmatory trial is to assess whether fever control at normothermia can improve the evolution of organ failure and mortality at day 60 of febrile patients with septic shock. This study will compare two strategies within the first 48 hours of septic shock: treatment of fever with cooling or no treatment of fever., Methods and Analysis: SEPSISCOOL II is a pragmatic, investigator-initiated, adaptive, multicentre, open-label, randomised controlled, superiority trial in patients admitted to the intensive care unit with febrile septic shock. After stratification based on the acute respiratory distress syndrome status, patients will be randomised between two arms: (1) cooling and (2) no cooling. The primary endpoint is mortality at day 60 after randomisation. The secondary endpoints include the evolution of organ failure, early mortality and tolerance. The target sample size is 820 patients., Ethics and Dissemination: The study is funded by the French health ministry and was approved by the ethics committee CPP Nord Ouest II (Amiens, France). The results will be submitted for publication in peer-reviewed journals., Trial Registration Number: NCT04494074., Competing Interests: Competing interests: FS is a member of the executive committee of the French Intensive Care Society (SRLF). All other authors declare no competing interests., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

4. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.

Author

Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabié A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustillères F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, and Yordanov Y

Subjects
Humans, Cohort Studies, Prospective Studies, SARS-CoV-2 genetics, Polymerase Chain Reaction, Lactams, Leucine, Nitriles, COVID-19 Testing, COVID-19
Abstract

Objectives: Our aim was to compare the clinical and virological outcomes in Omicron BA.1- and BA.2-infected patients who received sotrovimab with those in patients who received nirmatrelvir for the prevention of severe COVID-19., Methods: In this multi-centric, prospective ANRS 0003S CoCoPrev cohort study, patients at a high risk of progression of mild-to-moderate BA.1 or BA.2 COVID-19 who received sotrovimab or nirmatrelvir were included. The proportion of patients with progression to severe COVID-19, time between the start of treatment to negative PCR conversion, SARS-CoV-2 viral decay, and characterization of resistance variants were determined. A multi-variable Cox proportional hazard model was used to determine the time to negative PCR conversion and a mixed-effect model for the dynamics of viral decay., Results: Amongst 255 included patients, 199 (80%) received ≥3 vaccine doses, 195 (76%) received sotrovimab, and 60 (24%) received nirmatrelvir. On day 28, new COVID-19-related hospitalization occurred in 4 of 193 (2%; 95% CI, 1-5%) sotrovimab-treated patients and 0 of 55 nirmatrelvir-treated patients (p 0.24). One out of the 55 nirmatrelvir-treated patients died (2%; 95% CI, 0-10%). The median time to negative PCR conversion was 11.5 days (95% CI, 10.5-13) in the sotrovimab-treated patients vs. 4 days (95% CI, 4-9) in the nirmatrelvir-treated patients (p < 0.001). Viral decay was faster in the patients who received nirmatrelvir (p < 0.001). In the multi-variable analysis, nirmatrelvir and nasopharyngeal PCR cycle threshold values were independently associated with faster conversion to negative PCR (hazard ratio, 2.35; 95% CI, 1.56-3.56; p < 0.0001 and hazard ratio, 1.05; 95% CI, 1.01-1.08; p 0.01, respectively)., Conclusions: Early administration of nirmatrelvir in high-risk patients compared with that of sotrovimab was associated with faster viral clearance. This may participate to decrease transmission and prevent viral resistance., (Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results